You would expect more from The New York Times. The article lacks depth in exploring potential downsides, broader accessibility, and possible conflicts of intere

You would expect more from The New York Times. The article lacks depth in exploring potential downsides, broader accessibility, and possible conflicts of interest. It feels somewhat like an infomercial for the drugs rather than an objective piece of investigative reporting.